- Despite slightly higher revenues for the quarter ended April 2026 (Q2 2026), Indies Pharma Jamaica Limited’s (INDIES’) profits slipped by 1.3% as rising costs had its side-effects.
- Q2 2026 revenues totalled $285.02Mn, up 5.6% relative to Q2 2025, suggesting that the company is recovering from the acute operational disruption caused by Hurricane Melissa in Q1. For context, revenues were down 14.0% for Q1 2026.
- However, cost of sales increased by 6.8% to $75.39Mn, compressing gross margin by 30 basis points to 73.6% for the quarter. Operating expenses also exhibited mild symptoms, rising 5.2% to $122.62Mn, largely driven by higher administrative costs. As a result, operating profits increased by 4.9% to $89.40 and margins inched down from 31.6% to 31.4%.
- Finance costs and exchange losses were more bitter pills to swallow. INDIES saw its finance costs increase by 33.2% to $19.66Mn. While the $1.0Bn refinancing improved the Company's debt maturity profile, allowing it to retire the $805Mn bond with this 5-year facility, the higher 9.5% interest rate, compared to the previous 7.5% and smaller principal resulted in elevated finance costs that continued to weigh on earnings. Meanwhile, its $0.37Mn in exchange losses was a reversal of $1.71Mn gains for Q2 2025.
- Despite near-term pressures, the company’s growth outlook is supported by the recent FDA approval of Regadenoson injection, a pharmacologic stress agent used in myocardial perfusion imaging. The drug has entered production and is poised to enter the market by the start of the next quarter.
- Overall, the integration of these drugs into the US market is expected to support strong business growth and serve as a major earnings driver. Additionally, the company is also actively researching to identify new generic drugs to introduce into the US market.
- Indies’ stock price has decreased by 6.7% since the start of the calendar year. The stock closed Tuesday’s trading session at $2.65 and currently trades at a P/E of 26.5x, which is above the Junior Market Health Sector Average of 21.5x.
(Sources: JSE& NCBCM research)
